Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Ivarmacitinib in Pediatric Classical Hodgkin Lymphoma
NCT07641010Phase 2Not yet recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jun 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 2 trial of ivarmacitinib in Classical Hodgkin Lymphoma (cHL), sponsored by Shanghai Jiao Tong University School of Medicine. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
Classical Hodgkin Lymphoma (cHL)
Beyond the preview
Go deeper on NCT07641010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07641010.